Death | Survival | p | RR (95 % CI) | |
---|---|---|---|---|
(n = 81) | (n = 306) | |||
Demographics | ||||
Men | 57 (70.4) | 207 (61.8) | 0.1 | 1.36 (0.89-2.09) |
Age > 65 y | 61 (75.3) | 219 (71.6) | 0.3 | 1.17 (0.74-1.83) |
Place of acquisition | ||||
Community acquired | 13 (16) | 97 (31.7) | 0.003 | 0.41 (0.22-0.78) |
Health care associated | 25 (30.9) | 112 (36.6) | 0.2 | 0.82 (0.53-1.24) |
Nosocomial | 43 (53.1) | 97 (31.7) | <0.001 | 2 (1.36-2.93) |
Origin of infection | ||||
Urinary | 38 (46.9) | 177 (57.8) | 0.05 | 0.71 (0.48-1.04) |
Biliary | 8 (9.9) | 41 (13.4) | 0.26 | 0.76 (0.39-1.47) |
Unknown | 9 (11.1) | 28 (9.2) | 0.36 | 1.18 (0.64-2.16) |
Intra-abdominal | 11 (13.6) | 23 (7.5) | 0.07 | 1.63 (0.96-2.77) |
Pneumonia | 8 (9.9) | 20 (6.5) | 0.21 | 1.41 (0.75-2.61) |
Catheter | 3 (3.7) | 13 (4.2) | 0.56 | 0.89 (0.32-2.52) |
Comorbidity | ||||
Diabetes | 21 (25.9) | 91 (29.7) | 0.3 | 0.86 (0.55-1.34) |
Ictus | 15 (18.5) | 55 (18) | 0.51 | 1.03 (0.63-1.69) |
Dementia | 16 (19.8) | 50 (16.3) | 0.28 | 1.2 (0.74-1.93) |
COPD | 15 (18.5) | 50 (16.3) | 0.38 | 1.12 (0.69-1.84) |
Chronic renal failure | 20 (24.7) | 48 (15.7) | 0.05 | 1.54 (1-2.37) |
Cardiac failure | 15 (18.5) | 41 (13.4) | 0.16 | 1.34 (0.83-2.18) |
Liver cirrhosis | 16 (19.8) | 28 (9.2) | 0.009 | 1.92 (1.23-3) |
Cancer | 33 (40.7) | 78 (25.5) | 0.006 | 1.71 (1.17-2.51) |
Metastatic tumor | 13 (16) | 20 (6.5) | 0.009 | 2.05 (1.28-3.3) |
Immunosuppression | 16 (19.8) | 49 (16) | 0.25 | 1.22 (0.76-1.97) |
Charlson ≥3 | 60 (74.1) | 149 (48.7) | <0.001 | 2.43 (1.54-3.84) |
Microbiology | ||||
E. coli | 65 (80.2) | 278 (90.8) | 0.009 | 0.52 (0.33-0.82) |
Multidrug resistant | 45 (55.6) | 132 (43.1) | 0.03 | 1.48 (1-2.19) |
Presentation | ||||
Sepsis severe or shock | 57 (70.4) | 68 (22.5) | <0.001 | 4.9 (3.2-7.51) |
Adequate empirical therapy | 34 (42) | 164 (53.6) | 0.04 | 0.69 (0.47-1.02) |
Adequate change for definitive therapy | 29 (32.1) | 109 (35.6) | 0.33 | 0.88 (0.58-1.34) |